Voyager Therapeutics 3Q 2026: Revenue $4.01M, EPS ($0.4) — 10-Q Summary

Voyager Therapeutics reported 3Q 2026 revenue of $4.01M, down 70% YoY, with a net loss of $24.69M, an 11.5% improvement. Collaboration revenue included $3.1M from Novartis and $0.5M from Neurocrine. The company reduced R&D and administrative expenses, extending its cash runway to Q2 2028.

Original reporting
Published Nov 5, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Voyager Therapeutics 3Q 2026: Revenue $4.01M, EPS ($0.4) — 10-Q Summary — source image
Decision brief

The 30-second read

$VYGRNeutralLow
01

Why it matters

The Q3 2026 results highlight a steep revenue decline but improved expense management, affecting short‑term price expectations.

02

Market read

Micro‑cap biotech earnings; limited immediate market impact but useful for sector‑specific risk assessment.

03

What to watch

Potential future cash runway into 2028 and upcoming IND/CTA clearances may support longer‑term valuation.

Relevance 6/10Novelty 6/10Timing: post-10Q release

Background

Voyager Therapeutics is a clinical‑stage biotech focused on gene‑therapy collaborations.

Company-level read

Ticker impact

$VYGRNeutralMedium confidence
Context

Voyager Therapeutics reported Q3 2026 revenue of $4.01M, a 70% YoY decline, and a narrowed net loss.

Expected impact

likely modest pressure as market prices in the steep revenue decline

Evidence & confidence

The sharp revenue decline outweighs the slight improvement in net loss, suggesting limited upside.

Market effects

Biotech sector may see slight caution as a peer reports weak collaboration revenue.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact given the micro‑cap size.

Counterpoint

The narrowed loss could signal improving cost discipline, offering a buying opportunity despite revenue drop.

Key entities

  • Voyager Therapeutics, Inc.

    Issuer of the 10‑Q filing.

  • Novartis

    Provides $3.1M of the collaboration revenue.

  • Neurocrine

    Provides $0.5M of the collaboration revenue.

Related articles

$VYGRMed

Voyager Therapeutics, Inc. (VYGR): Completion of Acquisition or Disposition of Assets

Voyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Voyager Reports Third Quarter 2026 Financial and Operating Results - VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment - - Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to en